Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.

about

Feasibility of re-biopsy and EGFR mutation analysis in patients with non-small cell lung cancer.

Item

http://www.wikidata.org/entity/Q54109845

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Feasibility of re-biopsy and E ...... th non-small cell lung cancer.

@en

Feasibility of re-biopsy and E ...... th non-small cell lung cancer.

@nl

type

Item

label

Feasibility of re-biopsy and E ...... th non-small cell lung cancer.

@en

Feasibility of re-biopsy and E ...... th non-small cell lung cancer.

@nl

prefLabel

Feasibility of re-biopsy and E ...... th non-small cell lung cancer.

@en

Feasibility of re-biopsy and E ...... th non-small cell lung cancer.

@nl

P1476

Feasibility of re-biopsy and E ...... th non-small cell lung cancer.

@en

P2093

Bo Gun Kho

http://www.w3.org/2001/XMLSchema#string

Cheol-Kyu Park

http://www.w3.org/2001/XMLSchema#string

Ha Young Park

http://www.w3.org/2001/XMLSchema#string

Hong-Joon Shin

http://www.w3.org/2001/XMLSchema#string

Jin Sun Chang

http://www.w3.org/2001/XMLSchema#string

Jung-Hwan Lim

http://www.w3.org/2001/XMLSchema#string

Sung-Chul Lim

http://www.w3.org/2001/XMLSchema#string

Tae-Ok Kim

http://www.w3.org/2001/XMLSchema#string

Yong-Soo Kwon

http://www.w3.org/2001/XMLSchema#string

Yoo-Duk Choi

http://www.w3.org/2001/XMLSchema#string

P2860

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Pembrolizumab for the treatment of non-small-cell lung cancer

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinoma

Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay.

P304

856-864

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1759-7714.12762

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

In-Jae Oh

P577

2018-05-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29761660

http://www.w3.org/2001/XMLSchema#string

P921

biopsy

P932

6026616

http://www.w3.org/2001/XMLSchema#string